Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
|Articles|August 24, 2019
- August 2019 Back to School
- Volume 85
- Issue 8
The Role of the Pharmacist With Cholesterol Management: Focusing on New Guidelines and PCSK9 Inhibitors
Continuing education for managing cholesterol with PCSK9 inhibitors.
Advertisement
Faculty
Joseph J. Saseen, PharmD, BCPS, BCACP, CLS, Professor and Vice Chair, Department of Clinical Pharmacy; Professor, Department of Family Medicine; University of Colorado Anschutz Medical Campus, Aurora Colorado
Educational Objectives
At the completion of this activity, the participant will be able to:
- Examine the pathophysiology, complications, and burden associated with hypercholesterolemia
- Identify updates to guidelines and the appropriate role of PCSK9 inhibitors in the management of hypercholesterolemia
- Explore various ways that pharmacists can make an impact and provide education for patients with hypercholesteremia to optimize outcomes
Target Audience: Pharmacists
Activity Type: Application
Release Date: August 12, 2019
Expiration Date: August 12, 2020
Estimated Time to Complete Activity: 2.0 hours
Fee: This lesson is offered for free at
Articles in this issue
about 7 years ago
A Hospital and Physician Share Liability for Prescribing Opioidsabout 7 years ago
Motivational Interviewing Offers a Path to Improved Adherenceabout 7 years ago
Drug Shortages Raise Critical Safety Concernsabout 7 years ago
Case Study: Albuterolabout 7 years ago
340B Specialists Help Maintain Program Integrityabout 7 years ago
How Can Patients Prevent and Treat Fall Allergies?about 7 years ago
Case Study: Vitamins for Eye Healthabout 7 years ago
Pet Peeves (August 2019)Advertisement
Related to this article
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
Pneumonic Plague: What Pharmacists Need to Know About Treatment
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5